Search alternatives:
significant estimates » significant time (Expand Search), significant rates (Expand Search)
estimates decrease » estimates decreased (Expand Search), estimated decrease (Expand Search), estimated release (Expand Search)
changes decrease » change increases (Expand Search), largest decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
Showing 121 - 140 results of 32,840 for search '(( significant estimates decrease ) OR ( significant ((changes decrease) OR (larger decrease)) ))', query time: 0.84s Refine Results
  1. 121
    Contribution of changes in population aging, population growth, and age-specific incidence rate to changes in incident cases of LC from 2004 to 2018 in China.

    Contribution of changes in population aging, population growth, and age-specific incidence rate to changes in incident cases of LC from 2004 to 2018 in China. by Ze-Xing Zhang (18074512)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 122
    The relationship between ecosystem multifunctionality and bacterial Chao1 estimated richness.

    The relationship between ecosystem multifunctionality and bacterial Chao1 estimated richness. by Melissa S. Shinfuku (19942206)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  3. 123
    Estimated results of the mediation effect.

    Estimated results of the mediation effect. by Getachew Magnar Kitila (19935139)

    Published 2024
    “…Therefore, it is vital to promote the use of renewable energy, effectively leverage the knowledge spillover effects of trade to decrease energy intensity and formulate pertinent policies aimed at curbing carbon emissions and addressing the imminent threat of climate change in Africa. …”
    Save to List
    Saved in:
  4. 124
    Significant changes in whole-brain voxelwise analysis.

    Significant changes in whole-brain voxelwise analysis. by José V. Pardo (8293983)

    Published 2020
    Save to List
    Saved in:
  5. 125
    Geniposide (Gen) significantly decreased the content of Hyp in bleomycin-induced PF mice’s lung tissue.

    Geniposide (Gen) significantly decreased the content of Hyp in bleomycin-induced PF mice’s lung tissue. by Jian-Bin Yin (19556105)

    Published 2024
    Save to List
    Saved in:
  6. 126
    CBP per cumulative year for daratumumab and pembrolizumab per vial.

    CBP per cumulative year for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  7. 127
    S4 Fig -

    S4 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  8. 128
    S1 Fig -

    S1 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  9. 129
    S5 Fig -

    S5 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  10. 130
    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.

    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  11. 131
    S3 Fig -

    S3 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 132
    S6 Fig -

    S6 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  13. 133
    CBP per cumulative indication for daratumumab and pembrolizumab per vial.

    CBP per cumulative indication for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  14. 134
    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation.

    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 135
    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab.

    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 136
    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.

    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 137
    Input parameters for the base-case analysis.

    Input parameters for the base-case analysis. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 138
    S2 Fig -

    S2 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 139
    S1 Data -

    S1 Data - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  20. 140
    Changes in LC cases and deaths in male and female from 2004 to 2018, decomposed by three population-level determinants: population aging, population growth and epidemiological changes.

    Changes in LC cases and deaths in male and female from 2004 to 2018, decomposed by three population-level determinants: population aging, population growth and epidemiological chan... by Ze-Xing Zhang (18074512)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: